Real-world data (RWD) is transforming the life sciences industry, giving pharma companies valuable insights into the patient journey and helping more people get the life-saving treatments they need. To discuss
Dan Chancellor, VP, Thought Leadership, Lance Wolkenbrod, Senior Principal, RWD Solutions, and Dr. Madeline Naylor, Chief Clinician, at Norstella discuss real-world data in action and share a success story from
In episode two of Real-World Data After Dark, Lance Wolkenbrod, Senior Principal, RWD Solutions, and Dr. Madeline Naylor, Chief Clinician, test their real-world data expertise and share their perspectives on
Dan Chancellor, VP, Thought Leadership at Norstella, introduces Norstella’s real-world data experts, Dr. Madeline Naylor, Chief Clinician, and Lance Wolkenbrod, Senior Principal, RWD Solutions. The panel discuss what makes real-world
Pharma leaders agree that real-world data (RWD) is essential—but many still struggle to harness its full potential. In Real-World Data in 2025 and Beyond: Closing the Strategy Gap, Norstella surveyed
Real-world data has already proven its power to transform patient outcomes, accelerate clinical development, and strengthen commercial strategies, but its
From clinical trials to regulatory submissions to HEOR research, the value of real-world data (RWD) is clear. So how are
Finding the right patients and HCPs should be fast, but today’s cohorting process slows progress across the lifecycle. This infographic
Every day, patients are experiencing the life-changing impact of real-world data (RWD), and life sciences companies are feeling the business
Market access professionals tell us that their role is becoming increasingly influential amid a turbulent policy environment and intense competitive
Our latest research strongly suggests that a highly dynamic market access situation in the US is feeding back into upstream